ArticleThe Journal of infection2021
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- The Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillance.Pathogens (Basel, Switzerland) · 2023Article
- Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia.Nature communications · 2023Article
- Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.Virology journal · 2023Article
- Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions.Microbiology spectrum · 2023Article
- Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.Scientific reports · 2023Article
- Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants.Epidemiology and infection · 2023Article
- Article
- Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d'Ivoire.PLOS global public health · 2023Article
- Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up.Vaccines · 2022Article
- Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.Scientific reports · 2022Article
- Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies.Emerging infectious diseases · 2022Article
- The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study.BMJ open · 2022Article
- Article
- Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.Genome medicine · 2022Article
- Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.The Journal of infection · 2022Article
- Seroprevalence and infection attack rate of COVID-19 in Indian cities.Infectious Disease Modelling · 2022Article
- SARS-CoV-2 accessory proteins reveal distinct serological signatures in children.Nature communications · 2022Article
- Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the delta wave and vaccination.The Journal of infection · 2022Article
- Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England.EClinicalMedicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England.
methodsClinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression.
findingsIn total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12-16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50-68%) Euroimmun, 41% (30-52%) RBD, 10% (8-14%) Roche (N) < 2% Roche (S).
interpretationTrends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.